Wake Forest University Health Sciences: Lymphoma trials

The registry lists 10 Lymphoma studies with Wake Forest University Health Sciences as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 4Phase 2 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)CompletedNCT01988571Phase 2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other DiseasesCompletedNCT00453206Not applicableResults posted
• Telemedicine for Early Detection of Cytokine Release Syndrome and NeurotoxicityWithdrawnNCT04503538Not applicable
• Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS LymphomaCompletedNCT04022980Phase 1
• CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
• CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
• Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
• Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
• Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other DiseasesCompletedNCT00376922Not applicable